NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

NRx wins FDA approval for preservative-free ketamine and secures $11.25M DARPA contract.

What the company is saying

NRx Pharmaceuticals announces FDA approval of its Abbreviated New Drug Application for Preservative-Free Ketamine, positioning this as an immediate solution to the national ketamine shortage. The company frames the product as safer than current alternatives by eliminating benzethonium chloride, which the FDA has not designated as safe. Jonathan Javitt, MD, MPH, Chairman and CEO, emphasizes the strategic importance of ketamine supply and the ability to reshore sterile injectable manufacturing to the United States. The release highlights that commercial supply is already on hand and ready for labeling and distribution to hospitals and clinics. NRx also discloses a new $11.25 million contract from DARPA to conduct a phase 3 trial of NRX-101, combining it with robotic neuronavigated transcranial magnetic stimulation for depression. The company stresses regulatory momentum, noting NRX-100’s Fast Track Designation and NRX-101’s Breakthrough Therapy Designation for suicidal depression. The tone is confident and operationally focused, with regulatory and government validation presented as core value drivers.

What the data suggests

The FDA has approved NRx’s preservative-free ketamine ahead of the November 10 goal date, enabling immediate market entry. The company holds manufactured commercial supply and can begin supplying American hospitals and clinics, targeting anesthesia and pain control applications. The $11.25 million DARPA contract, awarded in October 2026, provides non-dilutive funding for a phase 3 trial of NRX-101 with robotic neuronavigated transcranial magnetic stimulation as a one-day depression treatment. NRX-100 has Fast Track Designation for suicidal ideation in depression, and NRX-101 has Breakthrough Therapy Designation for suicidal bipolar depression. No sales, revenue, or profitability data are disclosed for the ketamine product, and no comparative clinical outcome data are provided for the safety claims. The announcement is specific on regulatory and operational milestones but omits traditional financial performance metrics. All disclosed figures are realised, not projections.

Analysis

The announcement is largely factual and proportionate to the disclosed achievements. The FDA approval for Preservative-Free Ketamine is a realised milestone, and the company has manufactured commercial supply, enabling immediate market entry. The $11.25 million government contract for a phase 3 trial is a concrete, realised event, not a projection. Only one key claim is forward-looking: the pursuit of New Drug Approval for NRX-100, which is clearly separated from the main news. There is no evidence of exaggerated language or narrative inflation; the tone is positive but justified by the regulatory and operational milestones. However, the absence of any revenue, profit, or cash flow disclosure means the true_signal cannot exceed weak_positive, as investors cannot assess the financial impact or sustainability of these achievements.

Risk flags

• ●The absence of disclosed sales, revenue, or demand forecasts for preservative-free ketamine means the commercial impact is unquantified, leaving uncertainty about market uptake and financial contribution.
• ●Execution risk remains for the $11.25 million DARPA-funded phase 3 trial of NRX-101, as clinical trials can encounter delays, recruitment challenges, or negative results that would affect future value.
• ●While the company claims to address a national drug shortage and safety issue, no comparative clinical or market data are provided to substantiate the scale of unmet demand or the real-world safety advantage, limiting independent verification of the narrative.

Bottom line

NRx Pharmaceuticals has achieved a major regulatory milestone with FDA approval for preservative-free ketamine, allowing for immediate U.S. market entry and addressing a documented drug shortage. The $11.25 million DARPA contract for a phase 3 trial of NRX-101 adds non-dilutive funding and government validation to the pipeline. However, the company does not disclose any sales, revenue, or profitability data for the ketamine product, so the financial impact remains speculative. Claims of safety and strategic importance are not backed by comparative clinical or market data. Investors should focus on evidence of actual product uptake, revenue generation, and progress in the DARPA-funded trial as the next critical catalysts. The most important takeaway is that NRx now holds both regulatory approval and government funding, but the commercial and clinical outcomes are still to be demonstrated.

Announcement summary

(NASDAQ:NRXP) NRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine. The FDA approval was granted ahead of the previously announced November 10 approval goal date. Jonathan Javitt, MD, MPH, Chairman and Chief Executive Officer of NRx Pharmaceuticals, stated that the approval allows the company to bring Preservative-Free Ketamine to market, providing an option for repeat treatments without the risks associated with benzethonium chloride (BZT), a preservative classified as unacceptable for inclusion in multiple product categories by the FDA. Ketamine injection has been in short supply since 2018 and is currently on the FDA drug shortage list, with some manufacturers discontinuing production. The Secretary of Health and FDA Commissioner have identified ketamine as a strategic drug whose supply in the United States must be assured. NRx Pharmaceuticals has manufactured commercial supply and is now able to label and supply its product to American hospitals and clinics, where ketamine is primarily used for anesthesia and pain control, including labor and delivery. The company partnered with Nephron Pharmaceuticals in West Columbia, South Carolina, to demonstrate that sterile, preservative-free injectables can be manufactured in the United States. All currently available ketamine injection products contain BZT, which the FDA has declined to designate as Generally Recognized as Safe (GRAS). Under current FDA policy, BZT cannot be included in new drugs, consumer hand cleansers, wipes, healthcare or surgical hand rubs, or intravenous formulations above a threshold concentration for toxicological reasons. NRx Pharmaceuticals filed a Citizen Petition with the FDA to have BZT removed from ketamine, and an expert Toxicology report is available on the FDA docket, documenting that patients may be exposed to BZT levels exceeding the FDA's published maximum daily exposure of 1 milligram. Federal policymakers have addressed the threat posed by a sterile injectable drug supply largely manufactured offshore, and NRx's presentation of Ketamine demonstrates that manufacturing can be reshored to the United States. The FDA Office of Generic Drugs approved Ketamine ahead of its Generic Drug User Fee Act (GDUFA) goal date, demonstrating the agency's commitment to timely approval of drugs in shortage. The company will host a conference call at 8:30 a.m. ET on Friday, October 30, 2026, to discuss the FDA approval. NRx Pharmaceuticals is also seeking New Drug Approval for intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality. In October 2026, the Defense Advanced Research Projects Agency awarded an $11.25 million contract to NRx Pharmaceuticals to conduct a phase 3 trial of its oral drug NRX-101 (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for patients with depression. NRX-100 has been awarded Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

Disagree with this article?